BioSpace News Archive

This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.

Pathogens for antimicrobial resistance may still be a bit off peoples’ radar, but the lessons from unpreparedness of COVID-19 are in the mind of Qpex.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced interim safety and clinical activity data from the Phase 1/2 clinical trial of intravitreal 4D-125 in patients with advanced X-linked retinitis pigmentosa.

Chance Pharmaceuticals announced the completion of a $30 million Series C financing, led by new investor Lapam Capital with participation from new investors including CMS Capital and HEDA BioVenture and existing investor Guozhong Capital.

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that BRUKINSA® has been approved in Australia for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Kaneka Corporation has released KANEKA RT-PCR Kit SARS-CoV-2, a real-time PCR test kit capable of simultaneously detecting four variants of COVID-19.

Vitro Biopharma, Inc. dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2021, financial results of operations.